Streetbeat News

NAMS

NewAmsterdam Pharma Company N.V.

https://www.newamsterdampharma.com

Industry

Biotechnology

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

RBC Capital analyst Leonid Timashev has reiterated an Outperform rating for NewAmsterdam Pharma (NASDAQ:NAMS) and maintained a price target of $31.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 4:00 pm

Needham has initiated coverage on NewAmsterdam Pharma (NASDAQ:NAMS), highlighting its cholesterol drug obicetrapib as a potential blockbuster. The drug showed significant LDL-C reduction in trials, and Needham has set a Buy rating with a $36 price target. Obicetrapib could generate over $2 billion in sales, targeting 30 million patients.

Portfolio Pulse from Vandana Singh

August 28, 2024 | 5:33 pm

Needham analyst Serge Belanger has initiated coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Buy rating and set a price target of $36.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 10:46 am

NewAmsterdam Pharma reported Q2 revenue of $2.3 million and an EPS of $(0.41).

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:40 pm

NewAmsterdam Pharma (NASDAQ:NAMS) released positive topline data from its Phase 3 BROOKLYN trial for obicetrapib, showing significant LDL-C reduction in HeFH patients. Despite meeting primary endpoints, the stock experienced volatility, closing 8.35% lower. Analyst William Blair remains confident in the drug's potential, reiterating an Outperform rating.

Portfolio Pulse from Vandana Singh

July 30, 2024 | 7:10 pm

RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on NewAmsterdam Pharma (NASDAQ:NAMS) and maintained a $31 price target.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 1:39 pm

NewAmsterdam Pharma shares are trading lower after the company announced its phase 3 BROOKLYN trial results for Obicetrapib in reducing LDL-C.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 1:07 pm

Several major stocks, including Abbott Laboratories, Integra LifeSciences, and NewAmsterdam Pharma, experienced significant declines in Monday's pre-market session. Abbott fell due to a $495 million damages order, Integra LifeSciences dropped after lowering its FY24 outlook, and NewAmsterdam Pharma declined following Phase 3 trial results.

Portfolio Pulse from Avi Kapoor

July 29, 2024 | 12:24 pm

NewAmsterdam Pharma announced positive Phase 3 BROOKLYN trial results for Obicetrapib, showing significant reductions in LDL-C levels at both Day 84 and Day 365. The drug was well-tolerated with safety comparable to placebo. A conference call is scheduled for 8:30 AM ET today.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:04 pm

NewAmsterdam Pharma (NASDAQ:NAMS) will report topline data from its Phase 3 BROOKLYN clinical trial evaluating Obicetrapib in patients with heterozygous familial hypercholesterolemia on July 29, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 8:02 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.